Earnings Summary

Ascendis Pharma A/s’s revenue jumped 501.42% since last year same period to $137.7Mn in the Q4 2023. On a quarterly growth basis, Ascendis Pharma A/s has generated 186.68% jump in its revenue since last 3-months.

Ascendis Pharma A/s’s net profit jumped 58.11% since last year same period to $-86.88Mn in the Q4 2023. On a quarterly growth basis, Ascendis Pharma A/s has generated 46.45% jump in its net profits since last 3-months.

Ascendis Pharma A/s’s net profit margin jumped 93.04% since last year same period to -63.09% in the Q4 2023. On a quarterly growth basis, Ascendis Pharma A/s has generated 81.32% jump in its net profit margins since last 3-months.

Ascendis Pharma A/s’s earning per share (EPS) estimates for the current quarter stand at -1.6 - a 21.18% jump from last quarter’s estimates.

Ascendis Pharma A/s’s earning per share (EPS) estimates for the current year stand at -1.6.

Ascendis Pharma A/s’s earning per share (EPS) jumped 58.38% since last year same period to -1.54 in the Q4 2023. This indicates that the Ascendis Pharma A/s has generated 58.38% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Ascendis Pharma A/s’s return on assets (ROA) stands at -0.3.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Ascendis Pharma A/s’s return on equity (ROE) stands at -8.18.